Ongoing Studies:


The Genetic Contribution to Drug Induced Renal Injury:  The Drug Induced Renal Injury Consortium (DIRECT)

For more information on the DIRECT study click here:



Nephrotoxic Injury Negated by Just-in-Time Action.

NINJA is a multi-site kidney injury reduction quality improvement initiative.



Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children.

The HF20 study is being conducted by Gambro Renal Products, Inc. at the request of the FDA to support a 510(k) clearance for the Prismaflex HF20 set under an FDA approved IDE application.



A multi-center, pilot study to assess the safety and efficacy of a Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury.

This is an open-label, multi-center pilot study sponsored by CytoPherx, Inc.


Completed Studies:


The Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology (AWARE) study, creates the first prospective international pediatric all cause AKI data warehouse and biologic sample repository, providing a broad and invaluable resource for critical care nephrologists seeking to study risk factors, prediction, identification, and treatment options for a disease syndrome with high associated morbidity affecting a significant proportion of hospitalized children.

For more information on the AWARE study click here:



Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates was a 3-month restrospective chart review on eligible critically ill neonates admitted to neonatal intensive care units from centers in the Neonatal Kidney Collaborative (NKC). 

AWAKEN is the first research study from the NKC, an international collaborative multi-disciplinary group made up of neonatologists and pediatric nephrologist to investigate important questions related to neonatal AKI.